CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities

利用 CRISPR 技术在癌细胞球体中进行筛选,可识别出 3D 生长特异性脆弱性。

阅读:3
作者:Kyuho Han ,Sarah E Pierce ,Amy Li ,Kaitlyn Spees ,Gray R Anderson ,Jose A Seoane ,Yuan-Hung Lo ,Michael Dubreuil ,Micah Olivas ,Roarke A Kamber ,Michael Wainberg ,Kaja Kostyrko ,Marcus R Kelly ,Maryam Yousefi ,Scott W Simpkins ,David Yao ,Keonil Lee ,Calvin J Kuo ,Peter K Jackson ,Alejandro Sweet-Cordero ,Anshul Kundaje ,Andrew J Gentles ,Christina Curtis ,Monte M Winslow ,Michael C Bassik

Abstract

Cancer genomics studies have identified thousands of putative cancer driver genes1. Development of high-throughput and accurate models to define the functions of these genes is a major challenge. Here we devised a scalable cancer-spheroid model and performed genome-wide CRISPR screens in 2D monolayers and 3D lung-cancer spheroids. CRISPR phenotypes in 3D more accurately recapitulated those of in vivo tumours, and genes with differential sensitivities between 2D and 3D conditions were highly enriched for genes that are mutated in lung cancers. These analyses also revealed drivers that are essential for cancer growth in 3D and in vivo, but not in 2D. Notably, we found that carboxypeptidase D is responsible for removal of a C-terminal RKRR motif2 from the α-chain of the insulin-like growth factor 1 receptor that is critical for receptor activity. Carboxypeptidase D expression correlates with patient outcomes in patients with lung cancer, and loss of carboxypeptidase D reduced tumour growth. Our results reveal key differences between 2D and 3D cancer models, and establish a generalizable strategy for performing CRISPR screens in spheroids to reveal cancer vulnerabilities.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。